Beyond long COVID — how reinfections could be causing silent long term organ damage
Key Findings:
- This study demonstrates that tailored vaccines targeting patient-specific neoantigens (proteins that can trigger an immune response against cancer) can generate a potent immune response, with early data suggesting a correlation with improved long-term survival.
- A personalized multi-peptide neoantigen cancer vaccine called PGV001, using relatively few antigens (compared to recently published trials by other researchers) was sufficient to induce a strong immune response across multiple cancer types.
- Thirteen patients treated across five tumor types (non-small cell lung cancer, head and neck cancer, urothelial cancer, breast cancer, and multiple myeloma) experienced positive outcomes.
- Early results show that PGV001 did not cause serious side effects, and at five-year follow-up, of the 13 patients treated, six patients survived, and three of six surviving patients are tumor free.
David Putrino, PhD, discusses long COVID and reflects on the five years since the pandemic began. Learn more.
